derivados de benzoimidazol como inibidores de pad4

a presente invenção refere-se a compostos de fórmula (i): (i) em que x, y, r1 e r3-r11 são como aqui definidos, e sais dos mesmos são inibidores de pad4 e podem ser úteis no tratamento de vários distúrbios, por exemplo, artrite reumatoide, vasculite, lúpus eritematoso sistêmico, colite ulcerativa, c...

Full description

Saved in:
Bibliographic Details
Main Authors NEIL STUART GARTON, DOMINIQUE AMANS, ANN LOUISE WALKER, MATTHEW CAMPBELL, JOHN LIDDLE, HAWA DIALLO, CLEMENT DOUAULT, STEPHEN JOHN ATKINSON, CHRISTOPHER ROLAND WELLAWAY, MICHAEL DAVID BARKER, DAVID MATTHEW WILSON, ROBERT JOHN SHEPPARD, JESSICA FANNY RENAUX
Format Patent
LanguagePortuguese
Published 31.07.2018
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:a presente invenção refere-se a compostos de fórmula (i): (i) em que x, y, r1 e r3-r11 são como aqui definidos, e sais dos mesmos são inibidores de pad4 e podem ser úteis no tratamento de vários distúrbios, por exemplo, artrite reumatoide, vasculite, lúpus eritematoso sistêmico, colite ulcerativa, câncer, fibrose cística, asma, lúpus eritematoso cutâneo, e psoríase. Compounds of formula (I): wherein X, Y, R1 and R3-R11 are as herein defined, and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.
Bibliography:Application Number: BR20171124678